Artigos de revistas sobre o tema "BRAFV600E oncogene"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "BRAFV600E oncogene".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Algazi, Alain Patrick, Megan Othus, Benjamin Newell Voorhies, Kari Lynn Kendra, Shaker R. Dakhil, Amy K. Harker-Murray, Christopher D. Lao et al. "Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 10059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10059.
Texto completo da fonteRogounovitch, Tatiana I., Svetlana V. Mankovskaya, Mikhail V. Fridman, Tatiana A. Leonova, Victor A. Kondratovitch, Natalya E. Konoplya, Shunichi Yamashita, Norisato Mitsutake e Vladimir A. Saenko. "Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus". Cancers 13, n.º 13 (5 de julho de 2021): 3374. http://dx.doi.org/10.3390/cancers13133374.
Texto completo da fontePerna, Daniele, Florian A. Karreth, Alistair G. Rust, Pedro A. Perez-Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis et al. "BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model". Proceedings of the National Academy of Sciences 112, n.º 6 (26 de janeiro de 2015): E536—E545. http://dx.doi.org/10.1073/pnas.1418163112.
Texto completo da fonteKaabouch, Meryem, Hafsa Chahdi, Naima Azouzi, Mohammed Oukabli, Issam Rharrassi, Adil Boudhas, Hassan Jaddi et al. "BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study". African Health Sciences 20, n.º 4 (16 de dezembro de 2020): 1849–56. http://dx.doi.org/10.4314/ahs.v20i4.40.
Texto completo da fonteWang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang e Fei Xu. "BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review". Oncology Research and Treatment 45, n.º 1-2 (24 de novembro de 2021): 54–61. http://dx.doi.org/10.1159/000520453.
Texto completo da fonteZurnadzhy, Liudmyla, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Serhii Chernyshov, Sergii Masiuk e Vladimir A. Saenko. "The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age". Cancers 13, n.º 23 (30 de novembro de 2021): 6038. http://dx.doi.org/10.3390/cancers13236038.
Texto completo da fonteHosier, Gregory W., e Matthew T. Roberts. "Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma". Canadian Urological Association Journal 10, n.º 9-10 (13 de setembro de 2016): 306. http://dx.doi.org/10.5489/cuaj.3652.
Texto completo da fonteChabanet, Tamer Basel, Shannon Steinberg, Peisheng Zhang e Mary Jo Turk. "Elucidating the oncogene-driven regulatory T cell responses during melanoma tumorigenesis." Journal of Immunology 196, n.º 1_Supplement (1 de maio de 2016): 74.1. http://dx.doi.org/10.4049/jimmunol.196.supp.74.1.
Texto completo da fonteKidger, Andrew M., Linda K. Rushworth, Julia Stellzig, Jane Davidson, Christopher J. Bryant, Cassidy Bayley, Edward Caddye, Tim Rogers, Stephen M. Keyse e Christopher J. Caunt. "Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling". Proceedings of the National Academy of Sciences 114, n.º 3 (4 de janeiro de 2017): E317—E326. http://dx.doi.org/10.1073/pnas.1614684114.
Texto completo da fonteSpourquet, Catherine, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén et al. "BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages". Cancers 14, n.º 19 (26 de setembro de 2022): 4687. http://dx.doi.org/10.3390/cancers14194687.
Texto completo da fonteLee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim et al. "Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E". Journal of Clinical Endocrinology & Metabolism 96, n.º 1 (1 de janeiro de 2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
Texto completo da fontevon Soosten, Laura, Janina Haar, Veronika Frehtman, Stefan Holderbach, Julius Upmeier zu Belzen, Michael Jendrusch, Konstantin Okonechnikov et al. "THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing". Neuro-Oncology 24, Supplement_1 (1 de junho de 2022): i185—i186. http://dx.doi.org/10.1093/neuonc/noac079.695.
Texto completo da fonteAdamopoulos, Christos, Kostas A. Papavassiliou, Poulikos I. Poulikakos e Athanasios G. Papavassiliou. "RAF and MEK Inhibitors in Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 25, n.º 9 (24 de abril de 2024): 4633. http://dx.doi.org/10.3390/ijms25094633.
Texto completo da fonteBaldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang e Gabriele Toietta. "Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells". Cancers 11, n.º 5 (12 de maio de 2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Texto completo da fonteJiang, Cuiping, Lin Xie, Yiding Zhang, Masayuki Fujinaga, Wakana Mori, Yusuke Kurihara, Tomoteru Yamasaki, Feng Wang e Ming-Rong Zhang. "Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas". Molecular Imaging 17 (1 de janeiro de 2018): 153601211879595. http://dx.doi.org/10.1177/1536012118795952.
Texto completo da fonteRiesco-Eizaguirre, G., P. Gutiérrez-Martínez, M. A. García-Cabezas, M. Nistal e P. Santisteban. "The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane". Endocrine-Related Cancer 13, n.º 1 (março de 2006): 257–69. http://dx.doi.org/10.1677/erc.1.01119.
Texto completo da fonteRecagni, Tassinari, Doria, Cimino-Reale, Zaffaroni, Freccero, Folini e Richter. "The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands". Cells 8, n.º 10 (18 de outubro de 2019): 1274. http://dx.doi.org/10.3390/cells8101274.
Texto completo da fonteUribe-Alvarez, Cristina, Daniela Araiza-Olivera, Alexa Cannon e Jonathan Chernoff. "Abstract 4747: Novel targets for BRAFV600E and BRAFV600ERAC1P29S drug resistant melanoma". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 4747. http://dx.doi.org/10.1158/1538-7445.am2024-4747.
Texto completo da fonteWongchenko, Matthew J., Antoni Ribas, Paolo A. Ascierto, Brigitte Dréno, Anna Maria di Giacomo, Claus Garbe, Ilsung Chang et al. "Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study". JCO Precision Oncology, n.º 2 (novembro de 2018): 1–18. http://dx.doi.org/10.1200/po.17.00242.
Texto completo da fonteChaft, Jamie E., Scott Swanson, Jay M. Lee, Jules Lin, Hisashi Tsukada, Tianhong Li, R. Taylor Ripley et al. "Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial." Journal of Clinical Oncology 42, n.º 16_suppl (1 de junho de 2024): 8068. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8068.
Texto completo da fonteTosios, Konstantinos I., Eleni-Marina Kalogirou e Ioannis G. Koutlas. "Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression". International Journal of Molecular Sciences 25, n.º 4 (13 de fevereiro de 2024): 2238. http://dx.doi.org/10.3390/ijms25042238.
Texto completo da fonteStocksdale, Brian, Yaping Joyce Liao, Gwen Coffey e Seema Nagpal. "INNV-06. SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii117—ii118. http://dx.doi.org/10.1093/neuonc/noaa215.490.
Texto completo da fonteDimitrion, Peter, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou e Qing-Sheng Mi. "HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes". Blood 142, Supplement 1 (28 de novembro de 2023): 676. http://dx.doi.org/10.1182/blood-2023-185195.
Texto completo da fonteCangi, Maria Giulia, Riccardo Biavasco, Giulio Cavalli, Greta Grassini, Elena Dal-Cin, Corrado Campochiaro, Barbara Guglielmi et al. "BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease". Annals of the Rheumatic Diseases 74, n.º 8 (26 de março de 2014): 1596–602. http://dx.doi.org/10.1136/annrheumdis-2013-204924.
Texto completo da fonteHassan, Alaa A., Nasr K. Mohamed, Ashraf A. Aly, Mohamed Ramadan, Hesham A. M. Gomaa, Ahmed T. Abdel-Aziz, Bahaa G. M. Youssif, Stefan Bräse e Olaf Fuhr. "Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAFV600E". Molecules 28, n.º 24 (5 de dezembro de 2023): 7951. http://dx.doi.org/10.3390/molecules28247951.
Texto completo da fonteSigaud, Romain, Florian Selt, Thomas Hielscher, Nina Overbeck, Diren Usta, Marc Remke, Daniel Picard et al. "LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA". Neuro-Oncology 22, Supplement_3 (1 de dezembro de 2020): iii368. http://dx.doi.org/10.1093/neuonc/noaa222.396.
Texto completo da fonteGrob, Sydney, Lianna Nobre, Kurtis Davies, Scott Ryall, Dara Aisner, Lindsey Hoffman, Shadi Zahedi et al. "LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS". Neuro-Oncology 22, Supplement_3 (1 de dezembro de 2020): iii373. http://dx.doi.org/10.1093/neuonc/noaa222.416.
Texto completo da fonteSadangi, Shreyans, Katarina Milosavljevic, Edgardo Castro-Perez, Marcos Lares, Mithalesh Singh, Sarah Altameemi, David J. Beebe, Jose M. Ayuso e Vijayasaradhi Setaluri. "Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes". Cancers 14, n.º 5 (27 de fevereiro de 2022): 1233. http://dx.doi.org/10.3390/cancers14051233.
Texto completo da fonteAlaali, Lujain A., Ming Yuan, Chales Eberhart e Eric Raabe. "Abstract 3414: The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 3414. http://dx.doi.org/10.1158/1538-7445.am2023-3414.
Texto completo da fonteAlaali, Lujain, Eric Raabe, Micah Maxwell, Charles Eberhart e Hui Zhang. "DDDR-18. COMPREHENSIVE PROTEOMIC PROFILING OF BRAFV600E GLIOMA CELLS SHOWS UPREGULATION OF GLYCOLYSIS AND TCA CYCLE PROTEINS AFTER COMBINED MTOR AND MAP KINASE PATHWAY BLOCKADE". Neuro-Oncology 24, Supplement_7 (1 de novembro de 2022): vii102. http://dx.doi.org/10.1093/neuonc/noac209.383.
Texto completo da fonteTemprine, Kelsey, Nathaniel R. Campbell, Richard Huang, Erin M. Langdon, Theresa Simon-Vermot, Krisha Mehta, Averill Clapp, Mollie Chipman e Richard M. White. "Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance". Science Signaling 13, n.º 629 (28 de abril de 2020): eaau1453. http://dx.doi.org/10.1126/scisignal.aau1453.
Texto completo da fonteSong, Kai, Jenna K. Minami, Arthur Huang, Siavash R. Dehkordi, Shirley H. Lomeli, Jens Luebeck, Mark H. Goodman et al. "Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges". Cancer Discovery 12, n.º 4 (20 de dezembro de 2021): 1046–69. http://dx.doi.org/10.1158/2159-8290.cd-20-0936.
Texto completo da fonteCorso, Giovanni, Valeria Pascale, Giuseppe Flauti, Daniele Marrelli e Franco Roviello. "Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): e22037-e22037. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22037.
Texto completo da fonteNgiow, Shin Foong, Katrina M. Meeth, Kimberley Stannard, Deborah S. Barkauskas, Gideon Bollag, Marcus Bosenberg e Mark J. Smyth. "Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma". OncoImmunology 5, n.º 3 (10 de dezembro de 2015): e1089381. http://dx.doi.org/10.1080/2162402x.2015.1089381.
Texto completo da fonteLuciano, Angelo, Luigi Liguori, Giovanna Polcaro, Francesco Sabbatino e Stefano Pepe. "Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review". Clinics and Practice 13, n.º 6 (30 de novembro de 2023): 1549–60. http://dx.doi.org/10.3390/clinpract13060136.
Texto completo da fonteDrilon, Alexander E., Melissa Lynne Johnson, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Marzieh Golmakani, Micaela Reddy et al. "A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junho de 2023): 3020. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3020.
Texto completo da fonteRobb, Ryan, Linlin Yang, Changxian Shen, Adam R. Wolfe, Amy Webb, Xiaoli Zhang, Marall Vedaie et al. "Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair". Clinical Cancer Research 25, n.º 15 (16 de maio de 2019): 4749–60. http://dx.doi.org/10.1158/1078-0432.ccr-18-3625.
Texto completo da fonteAlotaibi, Sultan, Osama Alhafi, Hatem Nasr, Khalid Eltayeb e Ghaleb Elyamany. "Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature". Case Reports in Oncology 10, n.º 2 (14 de junho de 2017): 501–7. http://dx.doi.org/10.1159/000477336.
Texto completo da fonteDawar, Richa, Kunal Gawri, Estelamari Rodriguez, Deukwoo Kwon, Fahmin Basher, Philippos Apolinario Costa, Khadeja Khan, Tisdrey Torres, Chukwuemeka Ikpeazu e Gilberto Lopes. "Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): e21219-e21219. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21219.
Texto completo da fonteGeisen, Mariah, Josiane weber-Tessmann, Courtney Kelson, Daheng He, Chi Wang, Abu Saleh Mosa Faisal, Jill Kolesar e Yekaterina Zaytseva. "Abstract 4760: Inhibition of FASN postpones development of resistance to BRAF inhibitors in colorectal cancer". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 4760. http://dx.doi.org/10.1158/1538-7445.am2024-4760.
Texto completo da fonteRiesco-Eizaguirre, Garcilaso, Irene Rodríguez, Antonio De la Vieja, Eugenia Costamagna, Nancy Carrasco, Manuel Nistal e Pilar Santisteban. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer". Cancer Research 69, n.º 21 (27 de outubro de 2009): 8317–25. http://dx.doi.org/10.1158/0008-5472.can-09-1248.
Texto completo da fonteSchott, M. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer". Yearbook of Endocrinology 2010 (janeiro de 2010): 154–55. http://dx.doi.org/10.1016/s0084-3741(10)79511-1.
Texto completo da fontePricl, Sabrina, Erik Laurini, Domenico Marson e Gabriele Cavalieri. "Abstract C153: Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations". Molecular Cancer Therapeutics 22, n.º 12_Supplement (1 de dezembro de 2023): C153. http://dx.doi.org/10.1158/1535-7163.targ-23-c153.
Texto completo da fonteLim, Kee Siang, Zachary Wei Ern Yong, Huajing Wang, Tuan Zea Tan, Ruby Yun-Ju Huang, Daisuke Yamamoto, Noriyuki Inaki et al. "Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells". Journal of Biological Chemistry 295, n.º 19 (24 de março de 2020): 6387–400. http://dx.doi.org/10.1074/jbc.ra120.012943.
Texto completo da fonteChan, Lai N., Christian Hurtz, Huimin Geng, Franziska Auer, Zhengshan Chen, Gang Xiao, Jae-Woong Lee, Kadriye Nehir Cosgun, B. Hilda Ye e Markus Muschen. "Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling". Blood 132, Supplement 1 (29 de novembro de 2018): 1336. http://dx.doi.org/10.1182/blood-2018-99-115514.
Texto completo da fonteLiebig, Janika K., Silke Kuphal e Anja Katrin Bosserhoff. "HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth". Cancers 12, n.º 5 (21 de maio de 2020): 1299. http://dx.doi.org/10.3390/cancers12051299.
Texto completo da fonteKunz, Manfred, e Julio Vera. "Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers". Cancers 11, n.º 4 (3 de abril de 2019): 465. http://dx.doi.org/10.3390/cancers11040465.
Texto completo da fonteGroisberg, Roman, David S. Hong, Filip Janku, Yunfang Jiang, ChongJuan Wei, Daniel D. Karp, Apostolia Maria Tsimberidou et al. "SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients." Journal of Clinical Oncology 35, n.º 15_suppl (20 de maio de 2017): 2588. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2588.
Texto completo da fonteBorgenvik, Anna, Sean Misek, Alexander Zhang, Ruth Fekade, Timothy Ragnoni, Aaron Fultineer, Kevin Zhou et al. "LGG-29. BEYOND MAPK SIGNALING - GENOME-SCALE CRISPR/CAS9 SCREENS REVEAL NEW TARGETS FOR TREATMENT OF KIAA1549::BRAF-DRIVEN PEDIATRIC LOW-GRADE GLIOMA". Neuro-Oncology 26, Supplement_4 (18 de junho de 2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.422.
Texto completo da fonteLee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, Eun Kyung Choe, Eunyoung Kim, Rumi Shin, Seung Chul Heo et al. "Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study". Journal of Clinical Medicine 8, n.º 1 (17 de janeiro de 2019): 111. http://dx.doi.org/10.3390/jcm8010111.
Texto completo da fonte